Ramipril lowers plasma FGF-23 in patients with diabetic nephropathy

American Journal of Nephrology

Volumn 40, Issue 3, 2014, Pages 208-214

  Yilmaz, Mahmut Ilker ^a   Sonmez, Alper ^b   Saglam, Mutlu ^c   Kurt, Yasemin Gulcan ^a   Unal, Hilmi Umut ^a   Karaman, Murat ^a   Gok, Mahmut ^a   Cetinkaya, Hakki ^a   Eyileten, Tayfun ^a   Oguz, Yusuf ^a   Vural, Abdulgaffar ^a   Mallamaci, Francesca ^d   Zoccali, Carmine ^d  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b Departments of Endocrinology   (Turkey)

^c Departments of Radiology   (Turkey)

^d CNR   (Italy)

Author keywords

ACE inhibitor; Endothelial dysfunction; FGF 23; Proteinuria

Indexed keywords

AMLODIPINE; FIBROBLAST GROWTH FACTOR 23; RAMIPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBROBLAST GROWTH FACTOR; PHOSPHATE;

ADULT; ARTICLE; BLOOD LEVEL; BLOOD PRESSURE; CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; ENZYME INHIBITION; FEMALE; FUNCTION TEST; GLOMERULUS FILTRATION RATE; HUMAN; ISCHEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEINURIA; RENAL PROTECTION; VASODILATATION; BLOOD; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COMPLICATION; DISEASE COURSE; FOLLOW UP; INTERVENTION STUDY; MIDDLE AGED; PATHOLOGY; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; VASCULAR ENDOTHELIUM;

ADULT; AMLODIPINE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; ENDOTHELIUM, VASCULAR; FEMALE; FIBROBLAST GROWTH FACTORS; FOLLOW-UP STUDIES; HUMANS; INTERVENTION STUDIES; ISCHEMIA; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PHOSPHATES; PROTEINURIA; RAMIPRIL; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES;

EID: 84908310576     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000366169     Document Type: Article

References (34)

1. Wolf M: FGF23: fashion or physiology? Clin J Am Soc Nephrol 2010; 5: 1727-1729.
2. Hu MC, Shiizaki K, Kuro-o M, Moe OW: Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism. Annu Rev Physiol 2013; 75: 503-533.
3. Voormolen N, Noordzij M, Grootendorst DC, Beetz I, Sijpkens YW, van Manen JG, Boeschoten EW, Huisman RM, Krediet RT, Dekker FW: High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. Nephrol Dial Transplant 2007; 22: 2909-2916.
4. Kovesdy CP, Kalantar-Zadeh K: Serum phosphorus and the risk of progression of chronic kidney disease. Nephrol Dial Transplant 2007; 22: 3679-3680.
5. Norris KC, Greene T, Kopple J, Lea J, Lewis J, Lipkowitz M, Miller P, Richardson A, Rostand S, Wang X, Appel LJ: Baseline predictors of renal disease progression in the African American Study of Hypertension and Kidney Disease. J Am Soc Nephrol 2006; 17: 2928-2936.
6. Bellasi A, Mandreoli M, Baldrati L, Corradini M, Di NP, Malmusi G, Santoro A: Chronic kidney disease progression and outcome according to serum phosphorus in mild-tomoderate kidney dysfunction. Clin J Am Soc Nephrol 2011; 6: 883-891.
7. Zoccali C, Ruggenenti P, Perna A, Leonardis D, Tripepi R, Tripepi G, Mallamaci F, Remuzzi G: Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition. J Am Soc Nephrol 2011; 22: 1923-1930.
8. Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, Ritz E, Kronenberg F, Kuen E, Konig P, Kraatz G, Mann JF, Muller GA, Kohler H, Riegler P: Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 2007; 18: 2600-2608.
9. Scialla JJ, Astor BC, Isakova T, Xie H, Appel LJ, Wolf M: Mineral metabolites and CKD progression in African Americans. J Am Soc Nephrol 2013; 24: 125-135.
10. Wolf M, Molnar MZ, Amaral AP, Czira ME, Rudas A, Ujszaszi A, Kiss I, Rosivall L, Kosa J, Lakatos P, Kovesdy CP, Mucsi I: Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol 2011; 22: 956-966.
11. Gutierrez OM: Fibroblast growth factor 23 and disordered vitamin D metabolism in chronic kidney disease: updating the 'tradeoff' hypothesis. Clin J Am Soc Nephrol 2010; 5: 1710-1716.
12. Tang L, Both K, Taylor R: ACE inhibition and fibroblast growth factor in cultured human vascular smooth muscle. Vasc Med 1999; 4: 129-134.
13. Dai B, David V, Martin A, Huang J, Li H, Jiao Y, Gu W, Quarles LD: A comparative transcriptome analysis identifying FGF23 regulated genes in the kidney of a mouse CKD model. PLoS One 2012; 7:e44161.
14. Zanchi C, Locatelli M, Benigni A, Corna D, Tomasoni S, Rottoli D, Gaspari F, Remuzzi G, Zoja C: Renal expression of FGF23 in progressive renal disease of diabetes and the effect of ace inhibitor. PLoS One 2013; 8:e70775.
15. Yilmaz MI, Sonmez A, Saglam M, Yaman H, Kilic S, Demirkaya E, Eyileten T, Caglar K, Oguz Y, Vural A, Yenicesu M, Zoccali C: FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease. Kidney Int 2010; 78: 679-685.
16. G1A3 category (i.e. normal to high GFR and severely increased albuminuria) (Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group): KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013; 3: 1-150.
17. Yilmaz MI, Sonmez A, Saglam M, Yaman H, Cayci T, Kilic S, Eyileten T, Caglar K, Oguz Y, Vural A, Yenicesu M, Axelsson J: Reduced proteinuria using ramipril in diabetic CKD stage 1 decreases circulating cell death receptor activators concurrently with ADMA. A novel pathophysiological pathway? Nephrol Dial Transplant 2010; 25: 3250-3256.
18. Yilmaz MI, Carrero JJ, Martin-Ventura JL, Sonmez A, Saglam M, Celik T, Yaman H, Yenicesu M, Eyileten T, Moreno JA, Egido J, Blanco-Colio LM: Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilation. Clin J Am Soc Nephrol 2010; 5: 1174-1181.
19. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF III, Feldman HI, Kusek JW, Eggers P, Van LF, Greene T, Coresh J: A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612.
20. Celermajer DS, Sorensen K, Ryalls M, Robinson J, Thomas O, Leonard JV, Deanfield JE: Impaired endothelial function occurs in the systemic arteries of children with homozygous homocystinuria but not in their heterozygous parents. J Am Coll Cardiol 1993; 22: 854-858.
21. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R: Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002; 39: 257-265.
22. Ibels LS, Alfrey AC, Haut L, Huffer WE: Preservation of function in experimental renal disease by dietary restriction of phosphate. N Engl J Med 1978; 298: 122-126.
23. Shuto E, Taketani Y, Tanaka R, Harada N, Isshiki M, Sato M, Nashiki K, Amo K, Yamamoto H, Higashi Y, Nakaya Y, Takeda E: Dietary phosphorus acutely impairs endothelial function. J Am Soc Nephrol 2009; 20: 1504-1512.
24. Wolf M: Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int 2012; 82: 737-747.
25. Hu MC, Kuro-o M, Moe OW: Klotho and kidney disease. J Nephrol 2010; 23(suppl 16):S136-S144.
26. Seiler S, Heine GH, Fliser D: Clinical relevance of FGF-23 in chronic kidney disease. Kidney Int Suppl 2009; 114 :S34-S42.
27. Zisman AL, Wolf M: Recent advances in the rapidly evolving field of fibroblast growth factor 23 in chronic kidney disease. Curr Opin Nephrol Hypertens 2010; 19: 335-342.
28. Zhou C, Lu F, Cao K, Xu D, Goltzman D, Miao D: Calcium-independent and 1,25(OH)2D3- dependent regulation of the renin-angiotensin system in 1alpha-hydroxylase knockout mice. Kidney Int 2008; 74: 170-179.
29. Yamazaki Y, Imura A, Urakawa I, Shimada T, Murakami J, Aono Y, Hasegawa H, Yamashita T, Nakatani K, Saito Y, Okamoto N, Kurumatani N, Namba N, Kitaoka T, Ozono K, Sakai T, Hataya H, Ichikawa S, Imel EA, Econs MJ, Nabeshima Y: Establishment of sandwich ELISA for soluble alpha-Klotho measurement: age-dependent change of soluble alpha-Klotho levels in healthy subjects. Biochem Biophys Res Commun 2010; 398: 513-518.
30. Haruna Y, Kashihara N, Satoh M, Tomita N, Namikoshi T, Sasaki T, Fujimori T, Xie P, Kanwar YS: Amelioration of progressive renal injury by genetic manipulation of Klotho gene. Proc Natl Acad Sci U S A 2007; 104: 2331-2336.
31. Sugiura H, Yoshida T, Tsuchiya K, Mitobe M, Nishimura S, Shirota S, Akiba T, Nihei H: Klotho reduces apoptosis in experimental ischaemic acute renal failure. Nephrol Dial Transplant 2005; 20: 2636-2645.
32. Yoon HE, Ghee JY, Piao S, Song JH, Han DH, Kim S, Ohashi N, Kobori H, Kuro-o M, Yang CW: Angiotensin II blockade upregulates the expression of Klotho, the anti-ageing gene, in an experimental model of chronic cyclosporine nephropathy. Nephrol Dial Transplant 2011; 26: 800-813.
33. Nagai R, Saito Y, Ohyama Y, Aizawa H, Suga T, Nakamura T, Kurabayashi M, Kuroo M: Endothelial dysfunction in the klotho mouse and downregulation of klotho gene expression in various animal models of vascular and metabolic diseases. Cell Mol Life Sci 2000; 57: 738-746.
34. Yilmaz MI, Sonmez A, Saglam M, Yaman H, Kilic S, Eyileten T, Caglar K, Oguz Y, Vural A, Yenicesu M, Mallamaci F, Zoccali C: Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial. Am J Kidney Dis 2012; 59: 177-185.